Interview: Alok Kanti – President and CEO, Bayer Canada
Alok Kanti, president and CEO of Bayer Canada, draws upon his 27 years of international experience with Bayer to discuss the strategic significance of the Canadian affiliate to Bayer’s global…
Bayer Inc. is a Canadian subsidiary of Bayer AG and the corporate headquarters for the Canadian healthcare operations. Bayer is a world-class innovation company in the life science businesses and creates innovative products, breakthrough treatments and healthier alternatives to improve the quality of life for people, animals and communities.
In Canada, Pharmaceuticals, Consumer Health, Animal Health and Radiology & Interventional operate from our headquarters in Mississauga, and the Crop Science Division operates the crop production business out of its head office in Calgary.
Together with its Covestro* business, Bayer improves quality of life for Canadians through products that fight disease, protect crops and animals, and provide high-performance materials for numerous daily life uses.
With more than 1,400 employees across the country, in 2014, Bayer had sales of $1.9 billion and invested $96 million in research and development in Canada. Globally, Bayer AG had sales of €42.2 billion and invested €3.6 billion in research and development.
Contact
Bayer Inc., 2920 Matheson Boulevard East, Mississauga, Ontario, L4W 5R6 Canada
Tel: +1 905-282-5541
Website: https://www.bayer.ca
Alok Kanti, president and CEO of Bayer Canada, draws upon his 27 years of international experience with Bayer to discuss the strategic significance of the Canadian affiliate to Bayer’s global…
Ingo Brandenburg, managing director of Bayer Taiwan, brings over two decades of international pharmaceutical experience spanning Asia, Latin America, and Europe. With previous leadership roles, he has cultivated a deep…
The latest news from German pharma, including looming drug pricing reform, Boehringer Ingelheim’s EUR 640 million acquisition of a Kyowa Kirin autoimmune drug, and BioNTech’s updated revenue guidance. Also covered…
A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled…
A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut…
Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom…
In 2024, global biopharma faced a challenging landscape shaped by geopolitical tensions and cost containment measures in key markets. Despite these pressures, most major players perhaps surprisingly opted to retain…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
This interview explores Bayer’s strategic initiatives across the Middle East and North Africa (MENA) region, highlighting its commitment to innovation, local talent development, and sustainability. Over the next few years,…
An overview of some of the top stories from China’s pharma industry, including the arrest of AstraZeneca China’s top executive; Pfizer’s USD 1 billion China investment; WuXi AppTec’s continuing revenue…
The latest news from German pharma, including why Merck KGaA is looking to life science M&A; positive outlooks for Bayer and STADA; BioNTech’s move into the AI lab assistant space…
A roundup of some of the top stories coming out of China’s pharma industry, including AstraZeneca’s USD 1.92 billion deal with CSPC; Bayer’s new Shanghai incubator; Genentech’s purchase of Regor…
A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in…
See our Cookie Privacy Policy Here
